Edwards Lifesciences Co. (NYSE:EW) Shares Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 50.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,543 shares of the medical research company's stock after purchasing an additional 10,283 shares during the period. EP Wealth Advisors LLC's holdings in Edwards Lifesciences were worth $2,261,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter valued at $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 77,833 shares of company stock worth $5,611,023 in the last ninety days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.5 %

Shares of EW opened at $74.67 on Friday. The stock has a 50 day moving average price of $71.43 and a 200 day moving average price of $71.47. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $43.89 billion, a price-to-earnings ratio of 10.71, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.66 earnings per share. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Finally, Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $79.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.